Scinai Biopharma Services Appoints Eilon Elmalem as Site Head of Yavne CDMO Facility
Rhea-AI Summary
Scinai Immunotherapeutics (NASDAQ: SCNI) announced that subsidiary Scinai Biopharma Services has appointed Eilon Elmalem as Site Head of its Yavne CDMO facility, effective June 14, 2026. He assumes responsibility for site operations and engineering, following a transition supervised by current site head Dr. Sylvia Kachalsky, who plans to retire later in 2026.
Elmalem has over 20 years of biotechnology and pharmaceutical leadership experience, including senior roles at Merck and Sigma-Aldrich Millipore, with a background in GMP facility expansion, capital programs, and complex organizational transformations.
Positive
- Experienced leader appointed Site Head of Yavne CDMO facility effective June 14, 2026
- Over 20 years of biotech and pharma engineering and operations experience brought into Scinai Biopharma Services
- Structured transition and knowledge transfer process underway under current site head to support operational continuity
Negative
- Current Yavne site head Dr. Sylvia Kachalsky expected to retire later in 2026 after transition completion
News Market Reaction – SCNI
In the May 20 session, SCNI declined 6.02%, reflecting a notable negative market reaction. Argus tracked a peak move of +7.3% during that session. Argus tracked a trough of -8.3% from its starting point during tracking. Our momentum scanner triggered 6 alerts that day, indicating moderate trading interest and price volatility.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Historical Context
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| May 15 | Conference roundtable | Positive | +0.2% | Company to lead strategic dermatology drug development roundtable in Europe. |
| Apr 24 | Private placement | Negative | +61.6% | Dilutive $2.61M financing with new ADS and warrant issuance for CDMO growth. |
| Apr 06 | CDMO reorganization | Positive | +1.7% | Completed reorganization creating dedicated CDMO subsidiary and 2026 revenue target. |
| Apr 01 | Full-year results | Negative | +12.1% | 2025 results showed low cash and net loss despite CDMO revenue growth. |
| Mar 19 | Conference presence | Positive | -0.7% | Showcased expanded CDMO platform and immunology pipeline at BIO-Europe Spring. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
News-driven reactions often diverged from headline tone, with several seemingly constructive updates followed by muted or opposite price moves.
Over the past six months, SCNI highlighted expansion of its CDMO platform, including the Recipharm Israel (Yavne) acquisition, a strategic reorganization, and conference visibility. Financing via a $2.61 million private placement strongly lifted the stock, while other operational or investor-relations updates produced modest or mixed reactions. Against this backdrop, the appointment of a new Yavne site head fits the ongoing build‑out of the CDMO business rather than a new financial or clinical inflection point.
Key Terms
cdmo technical
AI-generated analysis. How Rhea-AI works. Not financial advice.
Mr. Elmalem has worked with Scinai over the past two years as an external consultant and has supported the Company's CDMO activities and operational development efforts. More recently, he has been involved in the transition and operational integration planning of the Yavne facility. In his new role, Mr. Elmalem will assume responsibility for site operations while continuing to oversee engineering activities, supporting the continued growth and operational development of Scinai's CDMO platform.
Mr. Elmalem brings more than 20 years of experience in engineering, operations, process development, and industrial infrastructure management within the biotechnology and pharmaceutical industries. Prior to joining Scinai, he held senior leadership roles at Merck, Sigma-Aldrich Millipore, including VP of Engineering and Process Development, where he oversaw engineering, manufacturing, R&D, and operational activities across multiple sites in
Amir Reichman, Chief Executive Officer of Scinai, commented: "We are pleased to welcome Eilon into this important leadership role. Over the past two years, Eilon has become an integral part of the growth and operational development of our CDMO platform. His extensive international operational experience, engineering expertise, and leadership capabilities will support the anticipated continued expansion, operational excellence, and long-term growth of our Yavne CDMO facility."
The transition and knowledge transfer process began on May 10, 2026, under the supervision of the current site head, Dr. Sylvia Kachalsky, who will continue to support the transition to ensure continuity of operations and effective transfer of responsibilities. Upon completion of the transition process, Dr. Kachalsky is expected to begin retirement leave prior to her planned retirement later in 2026.
Mr. Reichman added: "I would also like to thank Sylvia for her leadership of the Yavne site over many years and for her important support throughout the transition and integration process following the acquisition from Recipharm. Her professionalism, operational expertise, and commitment have contributed significantly to the successful integration of the Yavne facility into Scinai Biopharma Services' expanding CDMO platform and to the establishment of the commercial collaboration framework with Recipharm."
About Scinai Immunotherapeutics
Scinai Immunotherapeutics Ltd. (NASDAQ: SCNI) is a biopharmaceutical company focused on the development of innovative immunology therapies. The Company is advancing a pipeline of therapeutic candidates licensed from the Max Planck Society and from PinCell S.r.l.
Scinai also owns Scinai Biopharma Services Ltd., a contract development and manufacturing organization (CDMO), providing development and manufacturing services to biotechnology and pharmaceutical companies.
For more information, please visit: www.scinai.com
Company Contacts
Business Development | +972 8 930 2529 | bd@scinai.com
Investor Relations – Allele Capital Partners | +1 978 857 5075 | aeriksen@allelecapital.com
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the
These statements are based on current expectations and assumptions and are subject to risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements. These risks and uncertainties include, without limitation, risks related to the Company's ability to execute its operational and strategic plans, successfully integrate acquired operations, expand its CDMO activities, attract and retain customers and partners, maintain operational continuity, execute on commercial collaboration activities, secure financing or non-dilutive funding, and general market, industry, regulatory, and economic conditions. More detailed information regarding these and other risks and uncertainties is included in the Company's filings with the
Forward-looking statements speak only as of the date of this press release. Except as required by applicable law, the Company undertakes no obligation to update or revise any forward-looking statements to reflect new information, future events, or otherwise.
Logo: https://mma.prnewswire.com/media/2310190/Scinai_Immunotherapeutics_Logo.jpg
View original content:https://www.prnewswire.com/news-releases/scinai-biopharma-services-appoints-eilon-elmalem-as-site-head-of-yavne-cdmo-facility-302777462.html
SOURCE Scinai Immunotherapeutics Ltd.